Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability

Dacomitinib (DMB) is a second-generation irreversible tyrosine kinase inhibitor (TKI) that is claimed to overcome the disadvantages of the resistance reported for first-line epidermal growth factor receptor (EGFR) TKIs. Towards the end of 2018, the US Food and Drug Administration approved DMB in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhameed, Ali S., Kadi, Adnan A., Attwa, Mohamed W., AlRabiah, Haitham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448865/
https://www.ncbi.nlm.nih.gov/pubmed/30947315
http://dx.doi.org/10.1371/journal.pone.0214598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448865/
https://www.ncbi.nlm.nih.gov/pubmed/30947315
http://dx.doi.org/10.1371/journal.pone.0214598

Ejemplares similares